AnaptysBio clears an early hurdle in low-stress PoC study for peanut allergy med -- big questions go unanswered
AnaptysBio $ANAB got a big boost out of some early and positive results for its peanut allergy med ANB020. It was a small, short study and several analysts had set the bar low for success in the Q1 catalyst.
Altogether researchers lined up 20 patients for the study. And of the 13 in the drug arm who exhibited moderate-to-severe symptoms going in, 6 (46%) demonstrated peanut tolerance to 500mg at an interim point in the Phase IIa study. And they offered a shout out that only 1 in 15 patients on drug exhibited allergy symptoms, compared to 4 of 5 in the placebo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
